The code-named 'RCI002' that this company has recently been investigacióning and developing is a proyecto to create a protein therapeutic with pain-relieving effects. This tratamiento is produced by synthesizing a protein gene in E. coli, expressing it, and then extracting the therapeutic substance. The approach involves optimizing a protein found in vivo and recombining it into a therapeutic capable of suppressing pain in the body over a prolonged period.
La empresa explained that this substance demostró a pain-free duration nearly 20 times longer than gabapentin — a pain reliever commonly administered in general hospitals for dolor crónico management. When 65 mg/kg of gabapentin (based on body weight) was administered to mice, alivio del dolor lasted about 4 hours, but when only 0.1 mg/kg of the RCI002 substance was administered, alivio del dolor lasted aproximadamente 3 days.
RudaCure está desarrollando a terapia génica approach that relieves and treats dolor crónico using a protein gene that regulates dolor crónico in vivo. This is because a single injection can be esperado to provide therapeutic effects for 2–3 years. El CEO Kim declaró: "Pain relievers, local anesthetics, and analgésicos narcóticos used in general hospitals are not fundamental tratamientos," adding, "Narcotic analgesics lose their effectiveness as tolerance develops or cause addiction."